Multi-Parametric Drug Screening identifies Vulnerabilities and Combination Treatment Strategies for Neuroblastoma Subtypes
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Heidelberg, Universität Heidelberg, Dissertation, 2024
- Keyword
-
Screening
Neuroblastom
Therapie
Kind
- Event
-
Veröffentlichung
- (where)
-
Heidelberg
- (who)
-
Universitätsbibliothek Heidelberg
- (when)
-
2024
- Creator
-
Herter, Sonja
- Contributor
- DOI
-
10.11588/heidok.00035454
- URN
-
urn:nbn:de:bsz:16-heidok-354545
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:47 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Herter, Sonja
- Oehme, Ina
- Universitätsbibliothek Heidelberg
Time of origin
- 2024
Other Objects (12)
DDX1 co-amplification confers collateral vulnerabilities in neuroblastoma
Blinding the CYCLOPS - Neuroblastoma vulnerabilities unveiled by 1p loss
Blinding the CYCLOPS - neuroblastoma vulnerabilities unveiled by 1p loss
N-Myc-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastoma
Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma
Architectural B-cell organization in skeletal muscle identifies subtypes of dermatomyositis
Architectural B-cell organization in skeletal muscle identifies subtypes of dermatomyositis
Ultra-high field MRI of human hippocampi: Morphological and multiparametric differentiation of hippocampal sclerosis subtypes
Vulnerabilities
A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia
Pharmaco-genetic screening identifies novel targets and multimodal therapeutic strategies for pancreatic cancer subtypes
DDX1 co-amplification confers collateral vulnerabilities in neuroblastoma
Blinding the CYCLOPS - Neuroblastoma vulnerabilities unveiled by 1p loss
Blinding the CYCLOPS - neuroblastoma vulnerabilities unveiled by 1p loss
N-Myc-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastoma
Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma
Architectural B-cell organization in skeletal muscle identifies subtypes of dermatomyositis
Architectural B-cell organization in skeletal muscle identifies subtypes of dermatomyositis
Ultra-high field MRI of human hippocampi: Morphological and multiparametric differentiation of hippocampal sclerosis subtypes
Vulnerabilities
A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia
Pharmaco-genetic screening identifies novel targets and multimodal therapeutic strategies for pancreatic cancer subtypes
DDX1 co-amplification confers collateral vulnerabilities in neuroblastoma
Blinding the CYCLOPS - Neuroblastoma vulnerabilities unveiled by 1p loss
Blinding the CYCLOPS - neuroblastoma vulnerabilities unveiled by 1p loss
N-Myc-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastoma
Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma
Architectural B-cell organization in skeletal muscle identifies subtypes of dermatomyositis
Architectural B-cell organization in skeletal muscle identifies subtypes of dermatomyositis
Ultra-high field MRI of human hippocampi: Morphological and multiparametric differentiation of hippocampal sclerosis subtypes
Vulnerabilities
A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia